drugset
Drugs / BG9418
last change Sep 2019 re-read 3 minutes ago

BG9418

also known as interferon beta-1a
Developed for
multiple sclerosis
Investigated by
Biogen

Trials 2

today NCT00828204 · Ph 3 NCT00784836 · Ph 3
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00828204 Jan 2009 → Jul 2010 multiple sclerosis Biogen Completed No outcome recorded
Phase 3 NCT00784836 Oct 2008 → Feb 2009 multiple sclerosis Biogen Terminated No outcome recorded Stop: Business

Press releases naming this drug 4 releases

DateIssuerRelease
2019-09-23 Biogen Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding biogen.com ↗
2015-10-08 Biogen Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS biogen.com ↗
2009-07-08 Biogen Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis biogen.com ↗
2009-06-22 Biogen Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis biogen.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BG9418 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00828204 ↗
1

NCT00784836 ↗
Known as interferon beta-1a “BG9418 (interferon beta-1a)” NCT00828204 ↗
Route Intramuscular “30 mcg intramuscular (IM) injections” NCT00828204 ↗